Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 7Neurofibromatosis 1 6Neoplasm Metastasis 6Solid Tumours 5Neoplasms 5Melanoma 5Neurofibroma, Plexiform 4Lung Neoplasms 3Colorectal Neoplasms 3Breast Neoplasms 2Biliary Tract Neoplasms 2Uveal Melanoma 1Solid Tumors 1Renal Insufficiency 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Muscle Invasive Bladder Cancer 1Locally Advanced or Metastatic Solid Tumors 1Kidney Neoplasms 1Healthy Volunteers Pharmacokinetic Study 1Disease Progression 1Differentiated Thyroid Cancer 1Colonic Neoplasms 1Advanced Non Small Cell Lung Cancer 1Advanced Cancer 1

Interventions

AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Healthy Volunteers Pharmacokinetic Study × AZD 6244 × Clear all
NCT01960374 2014-06-02

Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK

AstraZeneca

Phase 1 Completed
117 enrolled

Healthy Volunteers Pharmacokinetic Study

Data powered by HemOnc (CC BY 4.0) Colophon âš¡